HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CEOs Urge ‘Civility’ In Supply Chain Dealings; ‘We’re Going To Come Out Of This At Some Point’

Executive Summary

Today’s global supply chain is trying, but there’s opportunity amid the frustrations for companies to strengthen vendor and customer relations that pay off down the road, according to contract manufacturing and consumer product CEOs speaking to HBW Insight.

You may also be interested in...



Beauty Supply Chain Hampered By ‘Post-COVID Hangover,’ Geopolitical, Climate Change Impacts

The global beauty ingredient supply chain is functioning again after pandemic-related lockdowns and other disruptions, but companies are having to contend with regional challenges, geopolitical turmoil and the impacts of climate change, supply and distribution experts said at the IBA Supply Chain and Sustainability Summit.

‘Go Try To Find Some Zinc Gluconate’: The Dietary Supplement Supply Chain Entering 2022

Ingredients for immune health supplements are in short supply as high demand persists in the US. CEOs Mark LeDoux of Natural Alternatives International and Jim Emme of NOW Health Group, both on the Natural Products Association’s board of directors, discuss ongoing supply issues and best practices to avoid problems.

Unilever Squelches Dr. Squatch Comparative Claims In NAD Forum; Advertiser Can Keep Its 'Sh*t List’

Dr. Squatch was able to substantiate that it uses “no harmful ingredients” as well as certain claims about avoiding a “Sh*t list” of ingredients, but agreed to modify other claims the National Advertising Division deemed falsely disparage competitor products, such as Unilever’s Dove personal-care brand.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS152085

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel